PL3301447T3 - Odpowiedź przećiwnowotworowa na zmodyfikowane epitopy własne - Google Patents

Odpowiedź przećiwnowotworowa na zmodyfikowane epitopy własne

Info

Publication number
PL3301447T3
PL3301447T3 PL17194252T PL17194252T PL3301447T3 PL 3301447 T3 PL3301447 T3 PL 3301447T3 PL 17194252 T PL17194252 T PL 17194252T PL 17194252 T PL17194252 T PL 17194252T PL 3301447 T3 PL3301447 T3 PL 3301447T3
Authority
PL
Poland
Prior art keywords
epitopes
modified self
anticancer response
anticancer
response
Prior art date
Application number
PL17194252T
Other languages
English (en)
Inventor
Linda Gillian Durrant
Victoria Anne BRENTVILLE
Rachel Louise METHERINGHAM
Original Assignee
Scancell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Limited filed Critical Scancell Limited
Publication of PL3301447T3 publication Critical patent/PL3301447T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PL17194252T 2012-08-07 2013-08-07 Odpowiedź przećiwnowotworowa na zmodyfikowane epitopy własne PL3301447T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1214007.5A GB201214007D0 (en) 2012-08-07 2012-08-07 Anti-tumour immune responses to modified self-epitopes
PCT/GB2013/052109 WO2014023957A2 (en) 2012-08-07 2013-08-07 Anti-tumour response to modified self-epitopes
EP13750368.6A EP2883054B1 (en) 2012-08-07 2013-08-07 Anti-tumour response to modified self-epitopes
EP17194252.7A EP3301447B1 (en) 2012-08-07 2013-08-07 Anti-tumour response to modified self-epitopes

Publications (1)

Publication Number Publication Date
PL3301447T3 true PL3301447T3 (pl) 2021-09-06

Family

ID=46934958

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17194251T PL3287787T3 (pl) 2012-08-07 2013-08-07 Odpowiedź przeciwnowotworowa na zmodyfikowane epitopy własne
PL17194252T PL3301447T3 (pl) 2012-08-07 2013-08-07 Odpowiedź przećiwnowotworowa na zmodyfikowane epitopy własne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17194251T PL3287787T3 (pl) 2012-08-07 2013-08-07 Odpowiedź przeciwnowotworowa na zmodyfikowane epitopy własne

Country Status (16)

Country Link
US (4) US10233220B2 (pl)
EP (3) EP3287787B1 (pl)
JP (2) JP6490581B2 (pl)
KR (1) KR102203096B1 (pl)
CN (2) CN107043414A (pl)
AU (1) AU2013301341B2 (pl)
BR (1) BR112015002574A8 (pl)
DK (3) DK3287787T3 (pl)
ES (3) ES2681973T3 (pl)
GB (1) GB201214007D0 (pl)
IN (1) IN2014DN10629A (pl)
PL (2) PL3287787T3 (pl)
PT (3) PT3301447T (pl)
SG (2) SG11201407804RA (pl)
WO (1) WO2014023957A2 (pl)
ZA (1) ZA201409095B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170384B1 (en) 2007-07-02 2016-04-13 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
ES2674393T3 (es) * 2014-05-05 2018-06-29 Novio Th B.V. Método para el diagnóstico serológico de la artritis reumatoide
CN104360070B (zh) * 2014-11-28 2017-02-22 山东新创生物科技有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
GB201512703D0 (en) * 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2018046648A1 (en) * 2016-09-08 2018-03-15 Katholieke Universiteit Leuven Citrullinated peptides for diagnosis or treatment of diabetes
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
GB202005779D0 (en) * 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
CN114404570B (zh) * 2022-01-20 2023-05-30 中国药科大学 一种新型抗肿瘤转移多肽及其应用
KR102860185B1 (ko) * 2022-01-26 2025-09-17 서울대학교병원 알데하이드 탈수소효소 2 조절을 통한 탈모의 예방, 개선, 또는 치료를 위한 병용요법
CN115772526B (zh) * 2022-07-20 2025-01-24 西北农林科技大学 西瓜ClmiR159-3P及其前体基因的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508235A (ja) 1995-06-07 1999-07-21 アクゾ・ノベル・エヌ・ベー 腫瘍関連エピトープ
GB9924060D0 (en) 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
JP2002051785A (ja) * 2000-08-09 2002-02-19 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体ＣＬＮ−ＩｇＧによって認識される抗原エピトープのアミノ酸配列およびそれをコードするＤＮＡヌクレオチド配列
AU2002210407A1 (en) * 2000-10-27 2002-05-06 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
GB0102145D0 (en) 2001-01-26 2001-03-14 Scancell Ltd Substances
AU2002327704A1 (en) 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
EP1461001A4 (en) 2002-01-03 2010-03-31 Scripps Research Inst ASSOCIATED WITH CANCER EPITOP
WO2003084467A2 (en) 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
WO2004031230A2 (en) 2002-10-02 2004-04-15 F. Hoffmann-La Roche Ag Novel mhc ii associated peptides
US7670604B2 (en) * 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1695089A1 (en) * 2003-12-15 2006-08-30 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
CN1712964A (zh) * 2005-07-18 2005-12-28 山东省医药生物技术研究中心 类风湿性关节炎特异性抗原性标志物及其应用
US20070122414A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8404810B2 (en) * 2006-02-17 2013-03-26 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
BRPI0707948A2 (pt) * 2006-02-17 2011-05-17 Univ Indiana Res & Tech Corp inibição baseado em peptìdeo da interação capcna em cáncer
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CA2817054C (en) * 2007-07-27 2017-02-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
US8318172B2 (en) * 2008-02-08 2012-11-27 The Scripps Research Institute Breaking immunological tolerance with a genetically encoded unnatural amino acid
EP3070097A3 (en) * 2009-03-30 2016-11-23 Nestec S.A. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
CA2797868C (en) * 2010-05-14 2023-06-20 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US20130303460A1 (en) 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science RECOMBINANT T-CELL LIGANDS AND ANTIBODIES FOR BINDING TO B-CELLS FOR TREATING AUTOIMMUNE DISEASES
EP3045468B1 (en) 2011-04-05 2020-01-15 Fraunhofer Gesellschaft zur Förderung der Angewand Novel peptides and their use in diagnosis and treatment
US20120295292A1 (en) * 2011-05-19 2012-11-22 University Of South Carolina Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera
EP2715360B1 (en) 2011-05-27 2016-08-17 Nordic Bioscience A/S Detection of diagnostic peptides
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes

Also Published As

Publication number Publication date
DK3287787T3 (da) 2020-12-21
JP2015525569A (ja) 2015-09-07
ZA201409095B (en) 2016-09-28
WO2014023957A2 (en) 2014-02-13
PL3287787T3 (pl) 2021-06-14
DK2883054T3 (en) 2018-09-17
WO2014023957A3 (en) 2014-05-15
EP3287787B1 (en) 2020-09-23
SG11201407804RA (en) 2015-02-27
PT3287787T (pt) 2020-11-26
EP3301447A1 (en) 2018-04-04
CA2874515A1 (en) 2014-02-13
ES2681973T3 (es) 2018-09-17
JP2018197236A (ja) 2018-12-13
US12258377B2 (en) 2025-03-25
HK1206427A1 (en) 2016-01-08
ES2843777T3 (es) 2021-07-20
EP2883054B1 (en) 2018-06-13
US20210198334A1 (en) 2021-07-01
AU2013301341B2 (en) 2018-09-20
US20230192790A1 (en) 2023-06-22
AU2013301341A1 (en) 2014-12-18
EP3287787A1 (en) 2018-02-28
KR20150040314A (ko) 2015-04-14
EP3301447B1 (en) 2020-12-02
PT2883054T (pt) 2018-10-15
US20150232525A1 (en) 2015-08-20
US10233220B2 (en) 2019-03-19
GB201214007D0 (en) 2012-09-19
JP6490581B2 (ja) 2019-03-27
SG10201701001VA (en) 2017-05-30
CN107043414A (zh) 2017-08-15
CN104823054B (zh) 2019-03-26
KR102203096B1 (ko) 2021-01-14
BR112015002574A8 (pt) 2018-01-23
CN104823054A (zh) 2015-08-05
BR112015002574A2 (pt) 2017-11-07
DK3301447T3 (da) 2021-03-08
US20180346537A1 (en) 2018-12-06
EP2883054A2 (en) 2015-06-17
ES2833962T3 (es) 2021-06-16
IN2014DN10629A (pl) 2015-09-11
PT3301447T (pt) 2021-02-18

Similar Documents

Publication Publication Date Title
PL3301447T3 (pl) Odpowiedź przećiwnowotworowa na zmodyfikowane epitopy własne
PL3862010T3 (pl) Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała
PT2878018T (pt) Resumo
PT2819623T (pt) Resumo
PT2674413T (pt) Resumo
PT2831109T (pt) Resumo
PT2825212T (pt) Resumo
EP2873441A4 (en) EXTINGUISHERS
FI20125875A7 (fi) Jarru
EP2821664A4 (en) Brake disk
PT2879977T (pt) Cápsula para preparar bebidas
EP2920370A4 (en) POST
FI20125570L (fi) Koostumus päänsärkyjen estämiseen
PL2900453T3 (pl) Sposób wytwarzania tubek
EP2837387A4 (en) CANCER AGENT
BR302012004807S1 (pt) Configuracão aplicada em cápsula
HRP20190033T1 (hr) Pripravak
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran
TH1401003459B (th) วิธีการผลิตพุดดิ้ง
ES1077871Y (es) Cápsula para preparar infusiones
ES1076491Y (es) Dispositivo para evitar extravío de niños
TH1401006714B (th) แคปซูล
TH149269B (th) วิธีการเพาะปลูกต้นอ้อย
BR302012003603S1 (pt) Configuração aplicada em cápsula
BR302012004499S1 (pt) Configuracao aplicada em mictório